| Issue Date | Title | Author(s) |
| 8-Oct-2022 | Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer | Kerslake, R; Sisu, C; Panfilov, S; Hall, M; Khan, N; Jeyaneethi, J; Randeva, H; Kyrou, I; Karteris, E |
| 4-Jan-2023 | Deciphering the Role of microRNA Mediated Regulation of Coronin 1C in Glioblastoma Development and Metastasis | Mustafov, D; Karteris, E; Braoudaki, M |
| 23-Dec-2022 | Asprosin Exerts Pro-Inflammatory Effects in THP-1 Macrophages Mediated via the Toll-like Receptor 4 (TLR4) Pathway | Shabir, K; Gharanei, S; Orton, S; Patel, V; Chauhan, P; Karteris, E; Randeva, HS; Brown, JE; Kyrou, I |
| 15-Jun-2023 | Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study | Alizzi, Z; Gogbashian, A; Karteris, E; Hall, M |
| 17-Jul-2023 | Malignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data | Eastwood, M; Marc, ST; Gao, X; Sailem, H; Offman, J; Karteris, E; Fernandez, AM; Jonigk, D; Cookson, W; Moffatt, M; Popat, S; Minhas, F; Robertus, JL |
| 4-Aug-2023 | Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: Association with treatment outcomes | Alizzi, Z; Saravi, S; Khalique, S; Mcdonald, T; Karteris, E; Hall, M |
| 26-Jun-2023 | Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models | Kerslake, R; Belay, B; Panfilov, S; Hall, M; Kyrou, I; Randeva, HS; Hyttinen, J; Karteris, E; Sisu, C |
| 30-Jan-2024 | In Silico and In Vitro Mapping of Receptor-Type Protein Tyrosine Phosphatase Receptor Type D in Health and Disease: Implications for Asprosin Signalling in Endometrial Cancer and Neuroblastoma | Orton, S; Karkia, R; Mustafov, D; Gharanei, S; Braoudaki, M; Filipe, A; Panfilov, S; Saravi, S; Khan, N; Kyrou, I; Karteris, E; Chatterjee, J; Randeva, HS |
| 27-Dec-2022 | Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian Cancer | Kerslake, R; Panfilov, S; Mustafa, N; Hall, M; Kyrou, I; Randeva, H; Karteris, E; Godfrey, R |
| 25-Mar-2023 | Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting | Alizzi, Z; Roxburgh, P; Cartwright, D; McLaren, A; Park, S; Jones, R; Greening, S; Hudson, E; Green, C; Gray, S; Khalique, S; Karteris, E; Hall, M |
